David Axelrod

2.5k total citations
64 papers, 1.8k citations indexed

About

David Axelrod is a scholar working on Molecular Biology, Oncology and Modeling and Simulation. According to data from OpenAlex, David Axelrod has authored 64 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Molecular Biology, 24 papers in Oncology and 8 papers in Modeling and Simulation. Recurrent topics in David Axelrod's work include Mathematical Biology Tumor Growth (8 papers), Cancer Genomics and Diagnostics (7 papers) and Gene expression and cancer classification (7 papers). David Axelrod is often cited by papers focused on Mathematical Biology Tumor Growth (8 papers), Cancer Genomics and Diagnostics (7 papers) and Gene expression and cancer classification (7 papers). David Axelrod collaborates with scholars based in United States, Canada and France. David Axelrod's co-authors include Marek Kimmel, Kenneth J. Pienta, Robert Axelrod, Natalie McGregor, Michael A. Gealt, María Ángeles Martín, T. V. Gopalakrishnan, Rafael Bravo, Donald M. Miller and Arthur W. Nienhuis and has published in prestigious journals such as Science, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

David Axelrod

63 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
David Axelrod United States 22 826 429 372 321 293 64 1.8k
Jacob G. Scott United States 31 722 0.9× 654 1.5× 388 1.0× 704 2.2× 399 1.4× 138 2.8k
Joel S. Brown United States 30 1.1k 1.3× 686 1.6× 589 1.6× 1.2k 3.7× 656 2.2× 85 2.9k
Tomer Kalisky Israel 27 1.6k 2.0× 571 1.3× 349 0.9× 388 1.2× 83 0.3× 53 2.9k
Zvia Agur Israel 30 783 0.9× 744 1.7× 358 1.0× 279 0.9× 1.4k 4.6× 90 2.6k
Philipp M. Altrock United States 19 668 0.8× 488 1.1× 598 1.6× 513 1.6× 432 1.5× 42 2.0k
Grzegorz A. Rempała United States 22 735 0.9× 191 0.4× 234 0.6× 120 0.4× 132 0.5× 108 1.9k
Abhyudai Singh United States 32 3.8k 4.6× 330 0.8× 1.1k 2.9× 373 1.2× 141 0.5× 221 4.8k
Slimane Ben Miled Tunisia 8 1.7k 2.0× 301 0.7× 231 0.6× 501 1.6× 44 0.2× 40 2.7k
William S. Hlavacek United States 36 2.9k 3.6× 263 0.6× 402 1.1× 98 0.3× 107 0.4× 103 4.0k
Philip Gerlee Sweden 19 501 0.6× 337 0.8× 197 0.5× 238 0.7× 696 2.4× 57 1.3k

Countries citing papers authored by David Axelrod

Since Specialization
Citations

This map shows the geographic impact of David Axelrod's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Axelrod with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Axelrod more than expected).

Fields of papers citing papers by David Axelrod

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Axelrod. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Axelrod. The network helps show where David Axelrod may publish in the future.

Co-authorship network of co-authors of David Axelrod

This figure shows the co-authorship network connecting the top 25 collaborators of David Axelrod. A scholar is included among the top collaborators of David Axelrod based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Axelrod. David Axelrod is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cockrell, Chase & David Axelrod. (2022). Combination Chemotherapy of Multidrug-resistant Early-stage Colon Cancer: Determining Optimal Dose Schedules by High-performance Computer Simulation. Cancer Research Communications. 3(1). 21–30. 3 indexed citations
2.
Cockrell, Chase & David Axelrod. (2019). Optimization of Dose Schedules for Chemotherapy of Early Colon Cancer Determined by High-Performance Computer Simulations. Cancer Informatics. 18. 2410569108–2410569108. 9 indexed citations
3.
Axelrod, David, et al.. (2017). Effective chemotherapy of heterogeneous and drug-resistant early colon cancers by intermittent dose schedules: a computer simulation study. Cancer Chemotherapy and Pharmacology. 79(5). 889–898. 9 indexed citations
4.
Axelrod, David, et al.. (2012). Prognosis for Survival of Young Women with Breast Cancer by Quantitative p53 Immunohistochemistry. PubMed. 1(1). 52–64. 3 indexed citations
5.
Patel, Shyam A., et al.. (2011). Tolerance-like mediated suppression by mesenchymal stem cells in patients with dust mite allergy–induced asthma. Journal of Allergy and Clinical Immunology. 129(4). 1094–1101. 46 indexed citations
6.
Pienta, Kenneth J., Natalie McGregor, Robert Axelrod, & David Axelrod. (2008). Ecological Therapy for Cancer: Defining Tumors Using an Ecosystem Paradigm Suggests New Opportunities for Novel Cancer Treatments. Translational Oncology. 1(4). 158–164. 118 indexed citations
7.
Chapman, Judith‐Anne W., Naomi Miller, H. Lavina A. Lickley, et al.. (2007). Ductal carcinoma in situ of the breast (DCIS) with heterogeneity of nuclear grade: prognostic effects of quantitative nuclear assessment. BMC Cancer. 7(1). 174–174. 25 indexed citations
8.
Alexe, Gabriela, Sorin Alexe, David Axelrod, et al.. (2006). Breast cancer prognosis by combinatorial analysis of gene expression data. Breast Cancer Research. 8(4). R41–R41. 56 indexed citations
9.
Cardiff, Robert D., et al.. (2006). Histopathology as a Predictive Biomarker: Strengths and Limitations. Journal of Nutrition. 136(10). 2673S–2675S. 11 indexed citations
10.
Alexe, Gabriela, Sorin Alexe, David Axelrod, P. L. Hammer, & David Weissmann. (2005). Logical analysis of diffuse large B-cell lymphomas. Artificial Intelligence in Medicine. 34(3). 235–267. 28 indexed citations
11.
Axelrod, David. (2000). A monthly period of symptoms associated with benign prostatic hyperplasia. Urology. 55(3). 436–436. 1 indexed citations
12.
Chapman, Judith‐Anne W., Sandra R. Wolman, Yorghos Remvikos, et al.. (1998). Assessing genetic markers of tumour progression in the context of intratumour heterogeneity. Cytometry. 31(1). 67–73. 15 indexed citations
13.
Kimmel, Marek, et al.. (1997). Computer Simulation of Expansions of DNA Triplet Repeats in the Fragile X Syndrome and Huntington's Disease. Journal of Theoretical Biology. 188(1). 53–67. 12 indexed citations
14.
Axelrod, David, Yuriy Gusev, & Thomas Kuczek. (1993). Persistence of cell cycle times over many generations as determined by heritability of colony sizes of ras oncogene‐transformed and non‐transformed cells. Cell Proliferation. 26(3). 235–249. 10 indexed citations
15.
Kimmel, Marek, David Axelrod, & Geoffrey M. Wahl. (1992). A branching process model of gene amplification following chromosome breakage. Mutation Research/Reviews in Genetic Toxicology. 276(3). 225–239. 31 indexed citations
16.
Huang, Shaoming & David Axelrod. (1991). Altered post-translational processing of p21ras oncoprotein in a transformation-suppressed cell line.. PubMed. 6(7). 1211–8. 7 indexed citations
17.
Gamel, John W. & David Axelrod. (1991). Inheritance and regression toward the mean in heterogeneous cell populations. Cell Proliferation. 24(3). 281–292. 8 indexed citations
18.
Axelrod, David & Thomas Kuczek. (1989). Clonal heterogeneity in populations of normal cells and tumor cells. Computers & Mathematics with Applications. 18(10-11). 871–881. 9 indexed citations
19.
Krueger, Leslie J., Robert W. Terry, Andrew J. Sussman, Ann C. Tate, & David Axelrod. (1984). Interferon-Induced Growth Modulation: Low Dose Maintenance of the Antiproliferative Response. Journal of Interferon Research. 4(1). 29–40. 5 indexed citations
20.
Habel, Karl & David Axelrod. (1965). Continued viral influence in virus-free polyoma tumors.. The Mouseion at the JAXlibrary (Jackson Laboratory). 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jacob G. Scott Breakdown of academic impact, for papers by Joel S. Brown Breakdown of academic impact, for papers by Tomer Kalisky Breakdown of academic impact, for papers by Zvia Agur Breakdown of academic impact, for papers by Philipp M. Altrock Breakdown of academic impact, for papers by Grzegorz A. Rempała Breakdown of academic impact, for papers by Abhyudai Singh Breakdown of academic impact, for papers by Slimane Ben Miled Breakdown of academic impact, for papers by William S. Hlavacek Breakdown of academic impact, for papers by Philip Gerlee
Rankless by CCL
2026